• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MediWound Ltd. - Ordinary Shares (NQ:MDWD)

17.03 -0.42 (-2.41%)
Streaming Delayed Price Updated: 4:00 PM EST, Mar 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about MediWound Ltd. - Ordinary Shares

< Previous 1 2 3 Next >
News headline image
MediWound Files Annual Report on Form 20-F
March 05, 2026
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Reports Fourth Quarter and Full Year 2025 Financial Results
March 05, 2026
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Report Fourth Quarter and Full Year 2025 Financial Results
February 19, 2026
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Present at Upcoming Investor Conferences
February 17, 2026
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference
January 12, 2026
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries
December 10, 2025
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 20, 2025
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Report Third Quarter 2025 Financial Results
November 05, 2025
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid®
November 03, 2025
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares
September 29, 2025
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia
September 25, 2025
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress
September 02, 2025
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference
August 20, 2025
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 14, 2025
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers
August 13, 2025
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Report Second Quarter 2025 Financial Results
August 04, 2025
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 21, 2025
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers
May 13, 2025
Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®’s superior clinical performance and comparable safety profile to SANTYL® 
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Report First Quarter 2025 Financial Results
May 05, 2025
Conference call and webcast scheduled for Wednesday, May 21, 2025, at 8:30 a.m. Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
April 28, 2025
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
March 19, 2025
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Report Fourth Quarter and Full Year 2024 Financial Results
March 03, 2025
Conference call and webcast scheduled for Wednesday, March 19th at 8:30 a.m. Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care
February 25, 2025
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Present at the 45th Annual TD Cowen Health Care Conference
February 24, 2025
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers
February 12, 2025
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 04, 2025
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx® Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025
December 17, 2024
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update
November 26, 2024
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Report Third Quarter 2024 Financial Results
November 12, 2024
Conference Call and Webcast Scheduled for Tuesday, November 26, 2024, at 8:30 a.m. Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers
October 10, 2024
From MediWound Ltd.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap